Arctic Star closes $292,000 first tranche of financing
Momentum Public Relations
Press Release: January 30, 2019
Arctic Star Exploration Corp. has completed the first tranche of its previously announced non-brokered private placement, as described in its news release dated Jan. 24, 2019, pursuant to which it has issued an aggregate of 5.84 million units at a price of five cents per unit for gross proceeds of $292,000. Each unit consists of one common share in the capital of the company and one non-transferable share purchase warrant. Each warrant is exercisable into one additional share at a price of eight cents per share for a period of two years from the closing date. The company intends on completing additional tranches of the private placement. The securities issued under the private placement and the shares that may be issuable on exercise of the warrants are subject to a statutory hold period expiring on May 30, 2019.
The company paid a cash finder’s fee of $2,000 to a certain finder and issued 40,000 share purchase warrants to one finder in connection with the first tranche of the private placement. Each finder’s warrant is exercisable into one share at a price of eight cents per share for a period of two years from the date of issuance.
The company plans to use the proceeds from the private placement for development of the company’s Finland project and for general working capital.
We seek Safe Harbor.
- Published in Arctic Star Exploration, Mining, News Home
GROWPACKER – the next Amazon of cannabis?
GROWPACKER; THE NEXT AMAZON OF CANNABIS?
What could Amazon possibly offer to make them even more successful? Imagine they offered the manufacturing, branding, packaging and total distribution of every one of their client’s products.
Well that’s what California based GrowPacker does; except they do it for anything and everything related to the cannabis industry. With regards to everything I mean; non-alcoholic beverages, carbonated and non-carbonated beverages, water, candies, chocolate bars, brownies, cookies, creams, lotions, massage oils, vape oils, pre-rolls, flower and the list goes on…
Growpacker clients provide them with their cannabis and preferred product parameters, including product specs and with that information Growpacker turns it into a finished ingestible and edible product. Because let’s face it, if your still invested in cannabis stocks that don’t produce eatables, start smoking your profits away because you missed the boat.
On top of converting your THC and CBD into anything infused, Growpacker will take care of formulations, lab testing, packaging and; even the total distribution and transportation of your product. They have a turn key formula with all the required licenses to boot! And to make this even more delicious, the competitors are far behind. Growpacker was one of the first to begin this process and therefore have acquired all, I mean all, the necessary licenses to make this a growers dream come true. Currently Growpacker has +450 clients in the pipeline and nearly 100 that have started the on-boarding process for production with upwards of 10 inquires per day. If only all start-ups could be so fortunate…
Another satisfying point about Growpacker is that they do what they say. By the end of 2018 they said that they would have all their licences and they did. They also said that they are working on a high-profile brand relationship with THC infused beer start-up, Ceria Beverages Company, and it was solidified.
Speaking of Ceria, let’s look at the advisory board and shareholders of Growpacker. Keith Villa, the original founding member of Blue Moon Brewery, America’s #1 craft beer with annual revenue exceeding $250M and brand value of over $1B now owned and operated by MillerCoors, is a special advisor and shareholder to the company. He is also the one spearheading Ceria.
Furthermore, the special advisory board is made up of InterContinental Beverage Capital; (IBC) founders Joe Messina, Stephen F. Horgan and Doug Christoph who have all held top executive positions at Coca Cola and MillerCoors. (IBC) is involved in serving financial and operational planning, debt restructuring, investment, re-branding, business performance, revenue growth and profitability. These three powerhouses make it clear that Growpacker is starting on a solid business foundation.
And if this weren’t enough, Jon Cooper founding member of Ebbu Inc. a U.S hemp research company recently acquired by Canopy Growth Corporation for $429M USD is also a special advisor and shareholder. He brings everything research and development on the hemp platform to push the boundaries of cannabis tech.
Now if this is not a formula for success, I don’t know what is. Combining the turn key production and distribution formula with some of the most successful people in business along with a company who is far ahead of its competition, feels as comfortable a stock pick as a good old THC infused Ceria beer! Watch out Amazon, here comes Growpacker.
About Growpacker
Growpacker is a fully-licensed cannabis co-packing and bottling company that operates in California, now the worlds fifth largest economy and Americas largest consumer market. Taking a bifurcated approach on the industry, Growpacker will have the ability to manufacture products for both the regulated cannabis market (dispensaries) as well as the open market for products that are CBD only (grocery, convenience store, etc). They have proprietary THC & CBD infusion technologies, allowing them to design and manufacture the most premium cannabis-infused products on the market, including both water and oil-based products.
About Momentum PR
Momentum PR is a cutting-edge public and investor relations consulting agency, representing companies within the Canadian investment community.
Since 2009, Momentum PR has been servicing small and mid-cap Canadian-listed public companies, seeking to increase their exposure across North America. The focus at Momentum PR is on building and driving brand awareness. Momentum PR cultivates new audiences in the media and investment communities by proactively engaging interested parties on behalf of client companies, through online and offline channels.
Disclaimer:
All editorial content contained herein is solely the responsibility of Momentum PR and does not reflect, in any way, the opinions of Growpacker
—
Isabelle Arsenault
Media Relations
MomentumPR
p:+1.450.332.6939 m: +1.514.816.2611
w:www.momentumpr.com e: isabelle@momentumpr.com
- Published in Blog, Cannabis, growpacker, Marijuana, News Home, Technology
Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc.
Momentum Public Relations
Press Release: January 30, 2019
Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc.
Canada NewsWire
ORLEANS, ON, Jan. 30, 2019
The Proposed Transaction is expected to:
- provide Tetra with the most robust Pharmaceutical and Natural Health Products pipeline of any Cannabinoid company;
- provide Tetra with more pharmaceutical and natural health products;
- allow Tetra to sell these products worldwide;
- give Tetra access to Panag’s NHP portfolio which is not included in the present in-licensing agreement with Panag.
ORLEANS, ON, Jan. 30, 2019/CNW Telbec/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“), a leader in cannabinoid-based drug discovery and development (TSXV: TBP) (OTCQB: TBPMF), today announced it has entered into a definitive agreement (the “Agreement“) with the shareholders (the “Vendors“) of Panag Pharma Inc. (“Panag“) for the previously-announced acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the “Proposed Transaction“). Panag is a Canadian-based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag has developed innovative and patented formulations for the treatment of ocular diseases and other pain conditions such as general neuropathic pain. Their significant formulation expertise in the wellness market will allow Tetra to expand its commercial operations.
Dr. Guy Chamberland, CEO and CSO of Tetra stated, “In completing this acquisition of Panag Pharma we have not only acquired a large portfolio of cannabinoid derived pharmaceutical and natural health products but also a team of scientists that have a substantial amount of expertise in the field. Tetra Bio-Pharma looks forward to incorporating Panag into its operations and accelerating its various drug development programs including our second-generation inhaled program.”
Following the closing of the Proposed Transaction, it is expected that Panag will remain a separate subsidiary owned 100% by Tetra and provide Tetra with additional discovery and early phase drug development capacity. With this robust product pipeline, Tetra intends to continue to implement its out-licensing program to generate additional revenues via upfront payments, milestone payments, and royalties and actively pursue the clinical development of lead products.
According to Dr. Orlando Hung, a co-founder of Panag, “The Panag team is very excited to have this well-timed opportunity with Tetra Bio-Pharma, allowing us to continue our decades of translational cannabinoid research. Utilizing the expertise and support from Tetra Bio-Pharma, we are confident that our partnership and combined skills will position us to bring effective and safe cannabinoid-based medications, as well as more innovative cannabinoid delivery systems to market to help managing patients with pain and inflammation.”
Pursuant to the Agreement, Tetra would acquire 100% of the issued and outstanding shares of Panag for an aggregate consideration of $12,000,000, on a debt-free basis and subject to customary post-closing adjustments. The purchase price would be payable by Tetra delivering to the Vendors, on the closing date of the Proposed Transaction, (i) $3,000,000 in cash and (ii) $9,000,000 payable in common shares of Tetra (“Common Shares“), at a price per Common Share equal to the lesser of (i) the 10-day volume weighted average price of the Common Shares ending as of the date of the Agreement and (ii) the Discounted Market Price (as that term is defined in the policies of the TSX Venture Exchange (“TSXV“)) of the Common Shares as at the date that is three business days prior to the closing date of the Proposed Acquisition. The Agreement also contemplates the payment by Tetra to the Vendors of an aggregate amount of up to $15,000,000 in cash in milestone payments upon the achievement of operational targets associated with marketing approvals and commercialization of both human and veterinary drug products by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Tetra is committed to fund Panag’s research in an amount no less than $1,200,000 annually for a period of ten years after the closing date of the Proposed Acquisition. The milestone payments would be accelerated in the event of a bankruptcy, insolvency, failure of Tetra to make its funding commitments to Panag, change of control or sale of all of the assets of Tetra at any time until December 31, 2028. In addition, in the event of a change of control of Tetra within 24 months of the closing date of the Proposed Acquisition, the Vendors would be entitled to receive from Tetra an additional $10 million.
Two of the Vendors, Bill Cheliak and Gregory Drohan, are non-arm’s length parties to Tetra within the meaning of the rules of the TSXV. Mr. Cheliak is the Chairman of the board of directors of the Company (the “Board“) and Mr. Drohan is a director of the Company. The Proposed Transaction will not result in the issuance of securities to non-arm’s length parties as a group as payment of the purchase price exceeding 10% of the number of outstanding shares of the Company on a non-diluted basis.
The Board formed a special committee (the “Special Committee“) for purposes of evaluating the Proposed Transaction. The Special Committee was composed of Benoit Chotard and Carl Merton, both of whom have no interest in Panag or the Proposed Transaction. On December 24, 2018, the Special Committee received a fairness opinion (the “Fairness Opinion“) from Paradigm Capital stating that the purchase price under the Proposed Transaction is fair, from a financial point of view, to the shareholders of Tetra. In light of the Fairness Opinion and of other considerations and upon the recommendation of the Special Committee, the Board approved the Proposed Transaction. Because of their interests in the Proposed Transaction, Mr. Cheliak and Mr. Drohan recused themselves from all meetings and discussions of the Board relating to the Proposed Transaction and abstained from voting on the resolutions of the Board approving the Proposed Transaction.
The Company expects that the Proposed Transaction will be completed in February 2019. Completion of the Proposed Transaction remains subject to a number of conditions, including the receipt of the approval of the TSXV and such other closing conditions as are customary in transactions of this nature. There can be no assurance that such conditions will be satisfied and that the Proposed Transaction will be completed as described or at all.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Panag Pharma:
Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new approach to the treatment of chronic pain and inflammation.
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
DIAGNOS Welcomes Dr. Jean-Francois Yale to the Board of Directors
Momentum Public Relations
Press Release: January 29, 2019
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment of Dr. Jean-Francois Yale to its board of directors.
Dr. Yale is an endocrinologist, currently professor of medicine at the McGill University Department of Medicine. Dr. Yale chaired the Clinical and Scientific Section of the Canadian Diabetes Association from 1992-1994 as well as the Expert Committee that published the 2001 Clinical Practice Guidelines for the Prevention and Management of Diabetes. Dr. Yale’s research interests (210 publications) include the prevention of hypoglycemia in type 1 diabetes and he participated in numerous multicentre trials on new therapies for type 1 and type 2 diabetes.
“We are delighted to have Dr. Yale joining the Board. I am convinced that DIAGNOS will greatly benefit from his specialized interest in intensive management of type 1 and type 2 diabetes,” said Mr. Georges Hebert, Chairman of the board of directors of DIAGNOS.
The board of directors has approved a grant of 2,620,000 stock options to the directors and officers of the Corporation. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price of these options has been established at $0.05 per share. The expiry date to which these options can be exercised has been fixed to January 28, 2024.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com
- Published in Diagnos, Life Sciences, News Home, Technology
Cannara has cash, equivalents of $43.5M at Nov. 30
Momentum Public Relations
Press Release: January 29, 2019
Cannara Biotech Inc. (“Cannara” or the “Company”) (CSE: LOVE), is building a vertically integrated Cannabis company focused on cannabis derivative products, today announced its financial results for the three-month period ended November 30, 2018.
Q1 2019 HIGHLIGHTS
- Subsequent to quarter end, began trading on the CSE
- Cash and cash equivalents of $43.5 million at end of Q1
- Revenue from short-term leases of $518,443
- Dual share structure dissolved upon public listing resulting in a single class of common shares
“On January 14th, Cannara became a publicly traded cannabis company, marking a critical milestone for our company,” said Zohar Krivorot, President and CEO of Cannara. “As this release represents our first disclosure as a public company, we want to assure the investment community we understand that being public demands transparency, which is entirely consistent with our values of respect and integrity. As we grow, we will stay true to our aim of building a premier cannabis company, we will maintain these core values.”
Construction of the Company’s Farnham, Quebec facility continues to be a top priority for Cannara with steady progress made throughout the quarter. Recently, the Company expanded the scope of Phase One to include a slightly larger growth area and additional processing capabilities, including some R&D space and equipment. With an estimated annual capacity of 15,000 kg of cannabis to be completed in the first half of 2019, the Farnhamfacility represents a key plank in the Company’s strategy to attract and grow via joint ventures with industry leaders.
“With a comprehensive brand strategy, our large one-of-kind facility, strong balance sheet and an elite senior management team, the fundamentals that will define Cannara are rapidly taking shape,” continued Mr. Krivorot. “Our expanding profile is accelerating our business development initiatives, positioning 2019 to be eventful and transformative year for us as we prepare for the upcoming legalization of beverages and other derivative cannabis products.”
“We are in the enviable position of having our Phase One construction and capacity plans fully funded, allowing us to pursue our strategic growth with confidence,” said Lennie Ryer, CFO of Cannara. “No doubt we are in the early stages of our growth curve, however, with $55 million raised in 2018, including our recently closed oversubscribed go-public round, our progress is speaking to our potential.”
About Cannara Biotech Inc.
Cannara Biotech is building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility located in Farnham, less than 45 minutes from downtown Montreal. Leveraging Quebec’s low electricity costs, Cannara’s facility will produce high-grade indoor cannabis and derivative products for the Canadian and international markets. Working with partners from various industries, Cannara will generate licensing revenues, rental revenues and revenue streams from joint-venture arrangements leveraging this highly valuable property. For more information, visit our website: www.cannara.ca
ON BEHALF OF THE BOARD OF DIRECTORS
“Zohar Krivorot”
Zohar Krivorot
CEO and Director
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding “Forward-Looking” Information
This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content:http://www.prnewswire.com/news-releases/cannara-biotech-reports-first-quarter-results-300785779.html
SOURCE Cannara Biotech Inc.
View original content: http://www.newswire.ca/en/releases/archive/January2019/29/c3699.html
Contact:
Sabrina Williams, Communications Manager, sabrina.williams@cannara.ca, T: 514-543-4200 ext. 265; Zohar Krivorot, President & CEO, zohar@cannara.ca; Lennie Ryer CPA, CA, CFE, Chief Financial Officer, lennie@cannara.ca
- Published in Cannabis, Cannara, Marijuana, Medical Marijuana, News Home
Mondias announces agreement with Wisdom of Nature Brokerage to expand retail sales in Ontario and grants stock options
Momentum Public Relations
Press Release: January 25, 2019
Mondias Natural Products Inc (“Mondias” or “Company“), (TSX VENTURE: NHP) announces the signing of a sales representation agreement with Wisdom of Nature Brokerage, a company specializing in the retail sales of Natural Health Products in Ontario. Mondias through its recently acquired Holizen brand, has been operating successfully in the province of Quebec and is now expanding retail operations to Ontario for the first phase of its Canada wide distribution.
Other news
The Board of Directors of the Company has approved the granting of 2,550,000 stock options to directors, officers, consultants and employees of the Company. The exercise price of the options is $0.235 (the closing price of the shares on January 21, 2019). The options vest over a 3-year period.
The above-mentioned options have been granted pursuant to the Mondias’s Stock Option Plan. Following this stock option grant the Company has a total of 2,950,804 stock options outstanding, which represents less than 5% of the Company’s issued and outstanding common shares.
About Wisdom of Nature Inc.
With more than 25 years of experience in the Natural Health Food Industry, Wisdom of Nature, led by its president and CEO Corine Johnson, specializes in sales development and independent/mass market product listing across the province of Ontario. They represent top brands like Strauss, Joy of the Mountain, Nature’s Aid, Abundance Naturally, Cannanda and Pro Santé.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit : mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Life Sciences, Mondias Natural, News Home, Technology
CROP Farm to Produce 50 L of THC Oil and Applies for Chula Vista Dispensary Location
Momentum Public Relations
Press Release: January 24, 2019
Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it will, initially, be making 100,000 premium Moon Rock Cones at one of its California subsidiaries as it expands its footprint in the state.
The raw material will be finished cannabis from CROP’s Humboldt County farm which is trimmed, high grade flower and will be for distillate input for cartridges and pre-rolls cones that will then be dipped in kief (cannabis crystals) to make the infused cones. The infused cones will be Hempire and Evolution branded with custom filters bearing the name. Additional equipment to fulfill the order is expected to arrive shortly.
After some initial market research, the company has established the best-selling SKUS are cones and pens. The company has instructed its toll process partner to convert equivalent material to produce approximately 50 liters of oil to fill 75,000 half gram cartridges and 50,000 quarter gram disposable pens, as well as the company will roll and tube approximately 200,000 Hempire and evolution branded 1-gram infused cones.
The distributor has offices in Oakland and Orange County. The distribution network consists of approximately 350 licensed cannabis stores across California.
The farm will shortly be taking down an additional 10,000 sq. ft. of canopy crop for harvest. Additionally, the company has retained local engineers to plan and permit the 2019 expansion, including a proposed 30,000 sq. ft. automated greenhouse facility, extra vault space and security upgrades.
CROP also announced it has made a cannabis retail application in Chula Vista, California, for its Emerald Height’s brand and is working with its local partners to apply in additional municipalities.
CROP CEO, Michael Yorke, stated: “Having wide distribution of a premium organic Infused Cone with over 100,000 branded units and 125,000 pen cartridges set to be consumed in California, this is a major step forward for our brand portfolio and tenant farm.”
About CROP
CROP is publicly listed on the CSE and trades under the symbol “CROP”. CROP is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the California Project; the technological effects of California Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact:
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: http://www.cropcorp.com
Phone: +1(604)484-4206
SOURCE Crop Infrastructure Corp.
- Published in Business, CROP Infrastructure, hemp, Marijuana, Medical Marijuana, News Home
Crop Infrastructure’s Elite completes genetics lab
Momentum Public Relations
Press Release: January 23, 2019
Crop Infrastructure Corp.’s 49-per-cent-owned subsidiary, Elite Ventures, has completed its genetics, tissue culturing and micropropagation laboratory at the company’s Nevada tetrahydrocannabinol (THC) farm.
The lab will provide 10 million plant starts for the company’s 2,115 acres of cannabidiol (CBD) farms. By propagating in the lab, the company will save about $3.0-million in seed and planting costs for the 2019 season. In addition, the lab will also develop proprietary genetics to maximize yields and provide the company a production and quality lead with some 100 photocannabinoids, beginning with cannabinol (CBN) and cannabigerol (CBG).
The newly completed building will get its final inspection next week with the Cannabis Licensing Board for approval for recreational cannabis cultivation, production and commercial kitchen. The building blocks needed for the perimeter security wall have been ordered and are expected to be on site shortly for its construction.
Crop has announced a non-brokered private placement offering to raise up to $2-million by the issuance of up to 6,666,667 units at a price of 30 cents per unit. Each unit will consist of one common share of the company and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at an exercise price of 50 cents for a period of 24 months following the closing of the offering. Completion of the offering is subject to regulatory approval.
About Crop Infrastructure Corp.
Crop is focused on cannabis branding and real estate assets. The company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada cannabis farm, 2,115 acres of cannabidiol farms, extraction in Nevada, and joint ventures on West Hollywood and San Bernardino dispensary apps, with international focuses in Jamaica and Italy.
- Published in CROP Infrastructure, hemp, Marijuana, Medical Marijuana, News Home
DIAGNOS Announces an Extension to the Diabetic Retinopathy Screening Services Assisted by Artificial Intelligence (AI) at the CHUM
Momentum Public Relations
Press Release: January 22, 2019
DIAGNOS Inc. (“DIAGNOS” or the “Company”) (TSX Venture Exchange: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today, further to our initial news release dated June 5th, 2018, the extension through May 2019 of the technological showcase for the automated detection of Diabetic Retinopathy at the Centre Hospitalier de l’Université de Montréal (CHUM).
Technological showcase
DIAGNOS will continue screening for diabetic retinopathy at the CHUM until the end of May 2019. Because of excellent initial screening results, the administration of the CHUM has elected to extend the duration of the technological showcase to further appreciate the benefits.
AI for detection and triage
Our early detection service includes an automated AI analysis of fundus imagery together with a triage system according to the degree of severity. This proprietary service is only available via our CARA telehealth platform (Computer Assisted Retina Analysis).
Improving patient services
The DIAGNOS automated screening solution significantly increases accessibility for diabetic and hypertensive patients subject to annual screening. Screening is done at the service centre using fundus photography. The process is fast, painless, and very simple for the patient. The CARA platform will facilitate identification and expedited triage of patients suffering from retinopathies who have been referred to the ophthalmology department following a consultation at the endocrinology or diabetes clinic.
DIAGNOS is also announcing the resignation of Mr. Jean-Yves Thérien from his position as director and chairman of the audit committee of the Corporation due to personal reasons. “On behalf of my fellow board members, I would like to sincerely thank Jean-Yves for his dedication and important contribution to the development of DIAGNOS”, said Mr. Georges Hébert, Chairman of the Board of directors. The Corporation is in the process of finding Mr. Thérien’s replacement as chairman of the audit committee. In the interim, Mr. Hébert will assume the role of chairman of the audit committee.
About DIAGNOS
DIAGNOS has screened to date more than 250,000 diabetic patients. Thanks to the support of the Government of Quebec and our collaboration with the CHUM, this technological showcase will allow Diagnos to demonstrate our expertise in the province. We strongly believe this partnership will also help set up extensive screening campaigns in other Canadian provinces and in the United States.
About CARA
CARA is a proprietary tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com
- Published in Diagnos, Life Sciences, News Home, Technology
- 1
- 2